Core Viewpoint - The company, Chow Sang Sang, has addressed consumer concerns regarding the gold content of its products, confirming that the disputed item meets national standards for gold purity [2][4]. Group 1: Company Response - Chow Sang Sang issued a statement emphasizing its commitment to consumer rights and quality control, stating that all products undergo rigorous quality checks before leaving the factory [2]. - The company has pledged to enhance communication and service details to improve consumer experience and maintain high product quality standards [2]. Group 2: Regulatory Actions - The market supervision authority in Qingyuan City has accepted the complaint regarding the gold jewelry and organized mediation, leading to a third-party testing of the item in question [4]. - The testing results confirmed that the jewelry met the GB11887-2012 national standard for gold purity, with the report delivered to both the consumer and the company [4]. Group 3: Testing Results - Initial consumer complaints indicated discrepancies in gold content, with varying purity levels detected at different points on the pendant, ranging from 64.37% to 99.99% [4][5]. - The testing also revealed the presence of other metals such as iron, silver, and palladium in the pendant [5].

Core Viewpoint - The incident involving a consumer's complaint about a facial mask highlights a trust crisis within the beauty industry, particularly regarding product quality and consumer safety [1][4]. Company Overview - The company in question, Xi'an Juzhi Biological Technology Co., Ltd., was established in 2000 and went public on the Hong Kong Stock Exchange in 2022. It owns several brands, including Kefu Mei and Keli Jin, with Kefu Mei being a major product line [10]. - The company reported a revenue of 5.539 billion yuan for 2024, reflecting a year-on-year growth of 57.2%, and a net profit of 2.062 billion yuan, up 42.1% year-on-year. Kefu Mei accounted for 82% of the total revenue, with its sales increasing by 62.9% to 4.542 billion yuan [10]. Industry Context - The beauty industry is currently facing significant scrutiny over product safety and quality, as evidenced by multiple complaints against Juzhi Biological, including allegations of misleading advertising and unapproved ingredients [10]. - The company's research and development (R&D) investment appears to be insufficient, with an R&D expense ratio of only 1.9% in 2024, down from 2.1% in 2023. In comparison, competitors like Jinbo Biological, Huaxi Biological, and Beitaini have R&D expense ratios of 10.89%, 6.8%, and 6.07%, respectively [10].